Literature DB >> 24910445

Similar and contrasting dimensions of social cognition in schizophrenia and healthy subjects.

Urvakhsh Meherwan Mehta1, Jagadisha Thirthalli2, H D Bhagyavathi3, J Keshav Kumar4, D K Subbakrishna5, Bangalore N Gangadhar6, Shaun M Eack7, Matcheri S Keshavan8.   

Abstract

Schizophrenia patients experience substantial impairments in social cognition (SC) and these deficits are associated with their poor functional outcome. Though SC is consistently shown to emerge as a cognitive dimension distinct from neurocognition, the dimensionality of SC is poorly understood. Moreover, comparing the components of SC between schizophrenia patients and healthy comparison subjects would provide specific insights on the construct validity of SC. We conducted principal component analyses of eight SC test scores (representing four domains of SC, namely, theory of mind, emotion processing, social perception and attributional bias) independently in 170 remitted schizophrenia patients and 111 matched healthy comparison subjects. We also conducted regression analyses to evaluate the relative contribution of individual SC components to other symptom dimensions, which are important clinical determinants of functional outcome (i.e., neurocognition, negative symptoms, motivational deficits and insight) in schizophrenia. A three-factor solution representing socio-emotional processing, social-inferential ability and external attribution components emerged in the patient group that accounted for 64.43% of the variance. In contrast, a two-factor solution representing socio-emotional processing and social-inferential ability was derived in the healthy comparison group that explained 56.5% of the variance. In the patient group, the social-inferential component predicted negative symptoms and motivational deficits. Our results suggest the presence of a multidimensional SC construct. The dimensionality of SC observed across the two groups, though not identical, displayed important parallels. Individual components also demonstrated distinct patterns of association with other symptom dimensions, thus supporting their external validity.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Comparison to normal; Factor analysis; Remission; Schizophrenia; Social cognition

Mesh:

Year:  2014        PMID: 24910445     DOI: 10.1016/j.schres.2014.05.018

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  6 in total

Review 1.  Cognitive remediation in schizophrenia-The view from India.

Authors:  Smita N Deshpande; Triptish Bhatia; E Mohandas; Vishwajit L Nimgaonkar
Journal:  Asian J Psychiatr       Date:  2016-06-24

2.  Social cognition in schizophrenia: Factor structure of emotion processing and theory of mind.

Authors:  Julia Browne; David L Penn; Tenko Raykov; Amy E Pinkham; Skylar Kelsven; Benjamin Buck; Philip D Harvey
Journal:  Psychiatry Res       Date:  2016-05-31       Impact factor: 3.222

3.  Lower- and Higher-Level Social Cognitive Factors Across Individuals With Schizophrenia Spectrum Disorders and Healthy Controls: Relationship With Neurocognition and Functional Outcome.

Authors:  Lindsay D Oliver; John D Haltigan; James M Gold; George Foussias; Pamela DeRosse; Robert W Buchanan; Anil K Malhotra; Aristotle N Voineskos
Journal:  Schizophr Bull       Date:  2019-04-25       Impact factor: 9.306

4.  The difference of social cognitive and neurocognitive performance between patients with schizophrenia at different stages and influencing factors.

Authors:  Shengyun Chen; Yaxi Liu; Dennis Liu; Guican Zhang; Xiaoli Wu
Journal:  Schizophr Res Cogn       Date:  2021-02-25

5.  Social cognition in patients with first episode of psychosis in remission.

Authors:  Mahadev Singh Sen; Ritu Nehra; Sandeep Grover
Journal:  Indian J Psychiatry       Date:  2020-10-10       Impact factor: 1.759

6.  Evaluation of social cognitive measures in an Asian schizophrenia sample.

Authors:  Keane Lim; Sara-Ann Lee; Amy E Pinkham; Max Lam; Jimmy Lee
Journal:  Schizophr Res Cogn       Date:  2019-12-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.